Agios Pharmaceuticals (AGIO) Total Current Liabilities (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Total Current Liabilities data on file, last reported at $70.2 million in Q2 2026.

• Quarterly Total Current Liabilities changed 0.27% year-over-year to $70.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $70.2 million (changed 0.27% YoY) and the FY2025 annual result came in at $82.2 million, up 1.29% from the prior year.
• Total Current Liabilities grew to $70.2 million in Q2 2026, from $58.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $119.5 million in Q3 2024 to a low of $45.1 million in Q1 2023.
• A 5-year average of $64.5 million and a median of $60.7 million in 2022 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 52.55% — and 2024, when it surged 104.45%.
• Tracing AGIO's Total Current Liabilities over 5 years: stood at $62.6 million in 2022, then advanced by 8.5% to $68.0 million in 2023, then increased by 19.43% to $81.2 million in 2024, then advanced by 1.29% to $82.2 million in 2025, then retreated by 14.58% to $70.2 million in 2026.
• The last three Total Current Liabilities figures came in at $70.2 million (Q2 2026), $58.8 million (Q1 2026), and $82.2 million (Q4 2025), per Business Quant data.